Overview

A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease

Status:
Completed

Trial end date:
2020-05-25

Target enrollment:

Participant gender:

Summary

Treatment with iron isomaltoside and ferric carboxymaltose in subjects with iron deficiency anaemia due to inflammatory bowel disease and comparison of the incidence of hypophosphatemia

Phase:

Phase 4

Details

Lead Sponsor:

Pharmacosmos A/S

Treatments:

Ferric Compounds
Iron
Iron isomaltoside 1000